<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The malignant potential of colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> highly correlates with their pathological characteristics, such as size, histology and grade of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>Currently, based on these parameters, <z:mpath ids='MPATH_270'>adenomas</z:mpath> are characterized as "non-advanced or advanced" and patient surveillance is adjusted accordingly </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to investigate the correlation between the KRAS mutations and characteristics of non-advanced and advanced colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> for predicting the risk of increased malignant potential of <z:mpath ids='MPATH_270'>adenomas</z:mpath> that may influence the decision to offer follow-up endoscopic surveillance </plain></SENT>
<SENT sid="3" pm="."><plain>We used a mutagenic polymerase chain reaction - restriction fragment length polymorphism method to determine KRAS mutations in 164 colorectal <z:hpo ids='HP_0003745'>sporadic</z:hpo> polypoid <z:mpath ids='MPATH_270'>adenomas</z:mpath> (51 non-advanced-, 113 advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath>) and in 40 early colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>The method of mutation detection was validated according to recommendation for KRAS mutation testing in colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> of the European Quality Assurance Program </plain></SENT>
<SENT sid="5" pm="."><plain>The limit of detection of the assay was 3 % mutated DNA with a good reproducibility </plain></SENT>
<SENT sid="6" pm="."><plain>Evaluation of pathological characteristics was performed according to European Guidelines for Quality Assurance in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal Cancer</z:e> Screening and Diagnosis </plain></SENT>
<SENT sid="7" pm="."><plain>The morphological parameters of the <z:mpath ids='MPATH_270'>adenoma</z:mpath> such as size, histology, grade of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> are highly correlated with one another: an increasing <z:mpath ids='MPATH_270'>adenoma</z:mpath> size raised the proportion of villous histology and degree of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (<z:hpo ids='HP_0000001'>all</z:hpo> p &lt; 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>KRAS mutations were detected in 31 % of the non-advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath>, in 57.5 % of the advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath> and in 62.5 % of the early <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Most mutations occurred at codon 12 rather than at codon 13 (72 %, 82 %, 76 % versus 22 %, 17 %, 24 %, respectively) </plain></SENT>
<SENT sid="10" pm="."><plain>There was no significant difference in association of KRAS mutation with age, gender, location among non-advanced-, and advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath> and early <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>KRAS mutation was found more often in tubulovillous and villous <z:mpath ids='MPATH_270'>adenomas</z:mpath>, whereas <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS was observed more frequently in tubular <z:mpath ids='MPATH_270'>adenomas</z:mpath> (P &lt; 0.0001) and there was an increased prevalence of KRAS mutations in larger <z:mpath ids='MPATH_270'>adenomas</z:mpath> (P &lt; 0.0001) </plain></SENT>
<SENT sid="12" pm="."><plain>In this study KRAS mutation occurred with the same frequency in <z:mpath ids='MPATH_270'>adenomas</z:mpath> with low-grade (48 %) and high-grade (50 %) <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="13" pm="."><plain>KRAS mutation is very strongly associated with a villous architecture and through villous component expansion, KRAS mutations may increase risk of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> in <z:hpo ids='HP_0003745'>sporadic</z:hpo> colorectal polypoid <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
</text></document>